Skip to main content

Select Drug Profiles

Original Research

Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis

Claudio Faria, PharmD, MPH, Xuan Li, MS, Norman Nagl, PhD, Ali McBride, PharmD, MS

Stakeholder Perspective

Value of Selecting the Best Antiemetic Prophylactic Agent for Patients Using Chemotherapy

by Curtis Wander, PharmD

IMBRUVICA™ Approved For Previously Treated Chronic Lymphocytic Leukemia; Immediately Available Through Onco360®

2012 Annual Index

Mekinist™ (trametinib) & Tafinlar® (dabrafenib) Approved In Combination; Both Limited Distribution Products Immediately Available Via Onco360®

Brintellix (Vortioxetine) Receives FDA Approval for the Treatment of Major Depressive Disorder

Injectafer (Ferric Carboxymaltose Injection) Receives FDA Approval for the Treatment of Iron-Deficiency Anemia

Practice Management

Insurance Companies’ Perspectives on the Orphan Drug Pipeline

Robert Handfield, PhD, Josh Feldstein, BA

Stakeholder Perspective

Breakthrough Therapy, or Breakthrough Pricing?

by Atheer A. Kaddis, PharmD

Practice Management

“Project IMPACT: Diabetes” Care Model Improves Health Outcomes in Underserved Populations in 25 Communities with a High Incidence of Diabetes

Benjamin M. Bluml, RPh

Practice Management

Cost and Drug Utilization Patterns Associated with the Management of Rosacea

Caroline Helwick

Practice Management, Pulmonary

Rehospitalization Is Driving Costs in Pulmonary Arterial Hypertension

Page 161 of 244
Results 1601 - 1610 of 2438